Profile data is unavailable for this security.
About the company
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.
- Revenue in USD (TTM)277.79m
- Net income in USD-98.50m
- Incorporated2008
- Employees240.00
- LocationEsperion Therapeutics Inc3891 Ranchero DriveSuite 150, Suite 300ANN ARBOR 32960United StatesUSA
- Phone+1 (734) 887-3903
- Fax+1 (302) 655-5049
- Websitehttps://www.esperion.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanara Medtech Inc | 72.41m | -6.57m | 270.81m | 107.00 | -- | 6.49 | -- | 3.74 | -0.7788 | -0.7788 | 8.62 | 4.77 | 1.10 | 1.86 | 8.13 | 676,731.00 | -10.16 | -17.73 | -12.08 | -22.07 | 89.73 | 88.08 | -9.23 | -17.13 | 1.49 | -4.88 | 0.2577 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Rigel Pharmaceuticals Inc | 130.30m | -14.23m | 276.24m | 147.00 | -- | -- | -- | 2.12 | -0.8136 | -0.8136 | 7.45 | -1.70 | 1.06 | 1.05 | 5.24 | 886,401.40 | -11.59 | -28.82 | -19.93 | -47.26 | 92.41 | 97.88 | -10.92 | -35.76 | 1.48 | -1.73 | 2.00 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| Theravance Biopharma Inc | 62.02m | -45.65m | 387.95m | 99.00 | -- | 2.00 | -- | 6.26 | -0.924 | -0.924 | 1.25 | 3.96 | 0.1534 | -- | 4.12 | 626,434.30 | -11.29 | -40.51 | -12.00 | -48.50 | -- | -- | -73.61 | -305.27 | -- | -- | 0.1305 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Esperion Therapeutics Inc | 277.79m | -98.50m | 406.19m | 240.00 | -- | -- | -- | 1.46 | -0.8758 | -0.8758 | 1.84 | -1.77 | 0.9466 | 0.7763 | 5.49 | 1,157,450.00 | -33.56 | -69.45 | -64.71 | -101.81 | 81.82 | -- | -35.46 | -147.44 | 1.49 | 0.0972 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Elite Pharmaceuticals Inc | 66.45m | 19.58m | 430.83m | 64.00 | 21.08 | 7.40 | 20.46 | 6.48 | 0.0191 | 0.0191 | 0.064 | 0.0545 | 0.9892 | 2.91 | 4.98 | 1,038,252.00 | 29.15 | 19.07 | 36.18 | 24.29 | 45.27 | 46.63 | 29.47 | 20.77 | 2.09 | 1.44 | 0.1389 | 0.00 | 65.79 | 49.55 | 464.56 | -- | 111.50 | -- |
| Xeris Biopharma Holdings Inc | 181.41m | -59.56m | 438.06m | 377.00 | -- | -- | -- | 2.41 | -0.4215 | -0.4215 | 1.28 | -0.1295 | 0.5493 | 0.7428 | 4.99 | 481,201.60 | -18.04 | -43.60 | -23.57 | -56.57 | 83.72 | 78.23 | -32.83 | -143.08 | 1.69 | -1.59 | 1.09 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| Zevra Therapeutics Inc | 23.99m | -65.75m | 440.41m | 65.00 | -- | 10.82 | -- | 18.36 | -1.67 | -1.67 | 0.6106 | 0.7734 | 0.1919 | -- | 2.09 | 369,015.40 | -52.61 | -32.11 | -65.34 | -39.89 | 71.78 | -- | -274.10 | -128.42 | -- | -112.94 | 0.6423 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Aquestive Therapeutics Inc | 58.36m | -25.72m | 447.56m | 135.00 | -- | -- | -- | 7.67 | -0.3565 | -0.3565 | 0.7874 | -0.3896 | 0.6685 | 2.85 | 7.25 | 432,296.30 | -29.46 | -76.63 | -42.14 | -123.85 | 68.49 | 64.24 | -44.07 | -102.95 | 6.98 | -2.67 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| Eyepoint Pharmaceuticals Inc | 50.39m | -86.82m | 453.83m | 121.00 | -- | 1.94 | -- | 9.01 | -1.80 | -1.80 | 1.08 | 4.38 | 0.2016 | 1.10 | 8.18 | 416,454.50 | -34.74 | -40.44 | -47.07 | -47.79 | 91.35 | 83.45 | -172.29 | -186.23 | 4.69 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
| SIGA Technologies Inc | 172.96m | 83.97m | 476.03m | 45.00 | 5.74 | 2.84 | 5.63 | 2.75 | 1.16 | 1.16 | 2.41 | 2.35 | 1.02 | 0.5866 | 23.09 | 3,843,484.00 | 49.52 | 22.34 | 56.21 | 27.56 | 82.00 | 88.65 | 48.55 | 41.14 | 5.65 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -141.77m | 484.45m | 150.00 | -- | 2.79 | -- | -- | -3.54 | -3.54 | 0.00 | 4.01 | 0.00 | -- | -- | 0.00 | -78.65 | -40.63 | -87.52 | -43.67 | -- | -- | -- | -2,972.81 | -- | -- | 0.00 | -- | -- | -- | -36.31 | -- | -16.34 | -- |
| Emergent Biosolutions Inc | 1.10bn | -587.00m | 498.06m | 1.60k | -- | 1.26 | -- | 0.4519 | -11.24 | -11.24 | 21.13 | 7.30 | 0.597 | 2.39 | 4.53 | 688,875.00 | -31.80 | -2.94 | -49.34 | -3.66 | 27.18 | 53.24 | -53.26 | -5.95 | 0.5438 | -1.87 | 0.6906 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| SNDL Inc | 668.22m | -82.73m | 514.25m | 2.52k | -- | 0.5699 | -- | 0.7696 | -0.3167 | -0.3167 | 2.55 | 3.40 | 0.5988 | 4.63 | 33.15 | 265,588.90 | -7.67 | -24.44 | -8.32 | -27.94 | 25.04 | 22.49 | -12.82 | -62.17 | 2.98 | -- | 0.1125 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
| CorMedix Inc | 806.12k | -53.12m | 540.17m | 82.00 | -- | 11.57 | -- | 670.08 | -0.9262 | -0.9262 | 0.0141 | 0.8355 | 0.014 | -- | -- | 9,830.73 | -92.57 | -54.84 | -110.35 | -62.32 | -64.79 | 6.18 | -6,589.09 | -18,323.42 | 4.43 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
| Revance Therapeutics Inc | 243.90m | -283.87m | 543.82m | 597.00 | -- | -- | -- | 2.23 | -3.17 | -3.21 | 2.64 | -1.24 | 0.4466 | 1.35 | 9.18 | 408,542.70 | -51.97 | -55.55 | -61.40 | -63.20 | 71.53 | -- | -116.39 | -304.96 | 3.01 | -22.09 | 1.41 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
Data as of Oct 08 2024. Currency figures normalised to Esperion Therapeutics Inc's reporting currency: US Dollar USD
42.55%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Millennium Management LLCas of 10 Jun 2024 | 10.18m | 5.97% |
| Bellevue Asset Management AGas of 31 Mar 2024 | 9.94m | 5.84% |
| Wasatch Advisors LPas of 31 Mar 2024 | 9.13m | 5.36% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 8.76m | 5.14% |
| Great Point Partners LLCas of 31 Mar 2024 | 8.00m | 4.69% |
| Woodline Partners LPas of 31 Mar 2024 | 7.92m | 4.65% |
| D. E. Shaw & Co. LPas of 31 Mar 2024 | 5.14m | 3.02% |
| Deerfield Management Co. LPas of 28 Mar 2023 | 5.00m | 2.93% |
| BofA Securities, Inc.as of 31 Mar 2024 | 4.27m | 2.51% |
| Two Seas Capital LPas of 31 Mar 2024 | 4.17m | 2.44% |
More ▼
Data from 31 Mar 2024 - 15 May 2024Source: FactSet Research Systems Inc.
